| Methods |
"The two trials (Keitel 1993a and Keitel 1993b) tested three live attenuated vaccines." This paper reports the results of 2 randomised controlled trials carried out in the USA |
| Participants |
Healthy volunteers recruited at Texas A&M University and Texas Medical Center, aged between 18 and 40 years |
| Interventions |
"Keitel 1993b tested the CR influenza A/Los Angeles/2/87 (H3N2) CR 149 with different lots of CR 125 and CRB 117 used. CR 125, CR 90, and CR 149 express the hemagglutinin and neuraminidase of wild‐type A/Kawasaki (an A/Taiwan/1/86 [H1N1]‐Iike virus), A/Bethesda (an A/Mississippi/1/86 [H3N2]‐l and A/Los Angeles (an A/Sichuan/2/87 [H3N2]‐like virus), respectively, and the internal proteins of cold‐adapted influenza A/Ann Arbor/6/60 (H2N2). CRB 117 expresses the hemagglutinin and neuraminidase of wild‐type influenza B/Ann Arbor/1/ 86 and the internal proteins of cold‐adapted influenza B/Ann Arbor/1/66. Placebo was allantoid fluid” |
| Outcomes |
Mild upper respiratory symptoms. Fever >= 37.8 °C within 1 week after each inoculation |
| Notes |
See Keitel 1993a. Safety data only were extracted |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Unclear |
| Allocation concealment (selection bias) |
Unclear risk |
Unclear |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Unclear |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Unclear |
| Summary assessment |
Unclear risk |
Unclear |
